User menu

Prostate cancer screening: clinical impact of WHO calibration of Beckman Coulter Access (R) prostate-specific antigen assays

Bibliographic reference Fillee, Catherine ; Tombal, Bertrand ; Philippe, Marianne. Prostate cancer screening: clinical impact of WHO calibration of Beckman Coulter Access (R) prostate-specific antigen assays. In: Clinical Chemistry and Laboratory Medicine : Associated with FESCC and IFCC, Vol. 48, no. 2, p. 285-8 (2010)
Permanent URL
  2. Schröder Fritz H., Bangma Chris H., Roobol Monique J., Is It Necessary to Detect All Prostate Cancers in Men with Serum PSA Levels <3.0ng/ml? A Comparison of Biopsy Results of PCPT and Outcome-Related Information from ERSPC, 10.1016/j.eururo.2008.01.048
  3. Catalona William J., Partin Alan W., Slawin Kevin M., Brawer Michael K., Flanigan Robert C., Patel Anup, Richie Jerome P., deKernion Jean B., Walsh Patrick C., Scardino Peter T., Lange Paul H., Subong Eric N. P., Parson Robert E., Gasior Gail H., Loveland Kathleen G., Southwick Paula C., Use of the Percentage of Free Prostate-Specific Antigen to Enhance Differentiation of Prostate Cancer From Benign Prostatic Disease : A Prospective Multicenter Clinical Trial, 10.1001/jama.279.19.1542
  4. Kort S. A.R., Comparison of 6 Automated Assays for Total and Free Prostate-Specific Antigen with Special Reference to Their Reactivity toward the WHO 96/670 Reference Preparation, 10.1373/clinchem.2006.069039
  5. Roddam Andrew W, Rimmer Janet, Nickerson Claire, Ward Anthony Milford, , Prostate-specific antigen: bias and molarity of commercial assays for PSA in use in England, 10.1258/000456306775141731
  6. Semjonow Axel, Oberpenning Frank, Brandt Burkhard, Zechel Christian, Brandau Wolfgang, Hertle Lothar, Impact of free prostate-specific antigen on discordant measurement results of assays for total prostate-specific antigen, 10.1016/s0090-4295(96)00604-8
  7. Semjonow A., De Angelis G., Oberpenning F., Schmid H.-P., Brandt B., Hertle L., The clinical impact of different assays for prostate specific antigen : PSA ASSAYS, 10.1046/j.1464-410x.2000.00858.x
  8. Roddam A. W., Assessing the Clinical Impact of Prostate-Specific Antigen Assay Variability and Nonequimolarity: A Simulation Study Based on the Population of the United Kingdom, 10.1373/clinchem.2004.031138
  9. Stephan Carsten, Kramer Jürgen, Meyer Hellmuth-Alexander, Kristiansen Glen, Ziemer Sabine, Deger Serdar, Lein Michael, Loening Stefan A., Jung Klaus, Different prostate-specific antigen assays give different results on the same blood sample: an obstacle to recommending uniform limits for prostate biopsies, 10.1111/j.1464-410x.2007.06805.x
  10. Blijenberg B.G., Yurdakul G., Van Zelst B.D., Bangma C.H., Wildhagen M.F., Schröder F.H., Discordant performance of assays for free and total prostate-specific antigen in relation to the early detection of prostate cancer : FREE AND TOTAL PSA ASSAYS FOR DETECTING PROSTATE CANCER, 10.1046/j.1464-410x.2001.02374.x
  11. Stamey TA, International Federation of Clinical Chemistry. Clin Biochem, 31, 475 (1998)
  12. Rafferty B, Clin Chem, 46, 1310 (2000)
  13. Chan DW, Clin Chem, 46, 1291 (2000)
  14. Oberpenning Frank, Weining Christoph, Brandt Burkhard, De Angelis Gabriela, Heinecke Achim, Hamm Michael, Stieber Petra, Hertle Lothar, Schmid Hans-Peter, Semjonow Axel, A New Modification of the Chiron ACS Assay for Total Prostate-Specific Antigen Achieves Equimolar Response Characteristics and Improves the Detection of Prostate Cancer, 10.1515/cclm.2003.016
  15. Semjonow A, Clin Chem, 47, 1472 (2001)
  16. Stephan C., Interchangeability of Measurements of Total and Free Prostate-Specific Antigen in Serum with 5 Frequently Used Assay Combinations: An Update, 10.1373/clinchem.2005.059170
  17. Postma Rensbe, de Vries Shijn H., Roobol Monique J., Wildhagen Mark F., Schröder Fritz H., van der Kwast Theo H., Incidence and follow-up of patients with focal prostate carcinoma in 2 screening rounds after an interval of 4 years : Focal Prostate Carcinoma, 10.1002/cncr.20840
  18. Aus Gunnar, Damber Jan-Erik, Khatami Ali, Lilja Hans, Stranne Johan, Hugosson Jonas, Individualized Screening Interval for Prostate Cancer Based on Prostate-Specific Antigen Level : Results of a Prospective, Randomized, Population-Based Study, 10.1001/archinte.165.16.1857
  19. Schröder Fritz H., Carter H. Ballentine, Wolters Tineke, van den Bergh Roderick C.N., Gosselaar Claartje, Bangma Chris H., Roobol Monique J., Early Detection of Prostate Cancer in 2007, 10.1016/j.eururo.2007.10.047
  20. Roobol M. J., Grenabo A., Schroder F. H., Hugosson J., Interval Cancers in Prostate Cancer Screening: Comparing 2- and 4-Year Screening Intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam, 10.1093/jnci/djm101
  21. Stephan Carsten, Kahrs Anna-Maria, Klotzek Silke, Reiche Janett, Müller Christian, Lein Michael, Deger Serdar, Miller Kurt, Jung Klaus, Toward metrological traceability in the determination of prostate-specific antigen (PSA): calibrating Beckman Coulter Hybritech Access PSA assays to WHO standards compared with the traditional Hybritech standards, 10.1515/cclm.2008.129
  22. Slev Patricia R., La’ulu Sonia L., Roberts William L., Intermethod Differences in Results for Total PSA, Free PSA, and Percentage of Free PSA, 10.1309/jybpmfnuf6eyy9tb
  23. Vignati G, Int J Biol Markers, 22, 295 (2007)
  24. Jansen F. H., Roobol M., Bangma C. H., van Schaik R. H. N., Clinical Impact of New Prostate-Specific Antigen WHO Standardization on Biopsy Rates and Cancer Detection, 10.1373/clinchem.2007.102699
  25. Stephan C, Int J Biol Markers, 24, 65 (2009)